The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns patients of the risk of meningioma, a tumor in the lining of the brain.

The pill version of Novo Nordisk’s weight loss treatment Wegovy received Food and Drug Administration approval Monday, marking the first oral GLP-1 medication that will soon hit the market. The ...

Novo Nordisk shares received a much-needed end of the year boost as the Wegovy maker became the first drugmaker to secure approval of a GLP-1 pill for weight loss, in what one analyst called a ...

U.S. stocks snapped a five-day win streak on Friday, amid small moves and low trading volume post the Christmas holiday. The blue-chip Dow Jones Industrial Average slipped -0.04% to 48,710.97 points, ...